Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate

Bibliographic Details
Main Authors:	Clerico, M, Faggiano, F, Palace, J, Rice, G, Tintore, M, Durelli, L
Format:	Conference item
Published:	2005

Similar Items

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
by: Clerico, M, et al.
Published: (2008)

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
by: Clerico, M, et al.
Published: (2008)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
by: Clerico, M, et al.
Published: (2006)

Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis
by: Clerico, M, et al.
Published: (2008)

Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials
by: Clerico, M, et al.
Published: (2007)

Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy
by: Clerico, M, et al.
Published: (2007)

Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis
by: Clerico, M, et al.
Published: (2008)

A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis
by: Clerico, M, et al.
Published: (2006)

To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
by: Clerico, M, et al.
Published: (2009)

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
by: Valéria Coelho Santa Rita Pereira, et al.
Published: (2012-10-01)

The best indication to early treat the clinically isolated syndrome based on the clinical onset. A Cochrane analysis
by: Clerico, M, et al.
Published: (2009)

New features of glatiramer acetate for the treatment of remitting multiple sclerosis
by: N. Y. Lasch
Published: (2015-12-01)

Pharmacoeconomic assessment of the effectiveness of glatiramer acetate (Copaxone®) in patients with multiple sclerosis
by: G. Ya. Shvarts
Published: (2005-06-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Nicolau syndrome following glatiramer acetate for multiple sclerosis: Case and review of reports
by: Methma Udawatta, et al.
Published: (2024-04-01)

Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients
by: María José Zarzuelo-Romero, et al.
Published: (2021-10-01)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
by: Genaro Gabriel Ortíz, et al.
Published: (2022-06-01)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
by: Arielle Kasindi, et al.
Published: (2022-05-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
by: Arthur Komlosh, et al.
Published: (2019-07-01)

Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate
by: Ioana S. Barac, et al.
Published: (2023-06-01)

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
by: Ignacio Casanova, et al.
Published: (2023-10-01)

GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
by: T. E. Shmidt
Published: (2016-12-01)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
by: Justin M. Honce, et al.
Published: (2020-09-01)

Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
by: Oliver Neuhaus, et al.
Published: (2021-03-01)

Neuroprotective Effect of Glatiramer Acetate on Neurofilament Light Chain Leakage and Glutamate Excess in an Animal Model of Multiple Sclerosis
by: Rina Aharoni, et al.
Published: (2021-12-01)

Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis
by: Ümmügülsüm Koc, et al.
Published: (2023-02-01)

Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
by: Fadi Towfic, et al.
Published: (2014-01-01)

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis
by: Sørensen, P, et al.
Published: (2010)

Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab
by: Andrius Kavaliunas, et al.
Published: (2023-05-01)

Interferon beta treatment of multiple sclerosis.
by: Markovitz, D
Published: (1994)

PHARMACOGENETICS OF INTERFERON BETA IN MULTIPLE SCLEROSIS
by: Mohamed Rayen Ganouni, et al.
Published: (2023-10-01)

A case of acute invasive fungal sinusitis in an immunocompetent patient on glatiramer acetate therapy
by: Melanie Hicks, et al.
Published: (2023-12-01)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
by: Sibley, W, et al.
Published: (1994)

Validation of the procedure for determination of amino acids composition of glatiramer acetate by C-13 NMR spectroscopy
by: N. E. Kuz’Mina, et al.
Published: (2018-02-01)

Inconsistent Effects of Glatiramer Acetate Treatment in the 5xFAD Mouse Model of Alzheimer’s Disease
by: Berke Karaahmet, et al.
Published: (2023-06-01)

Drug‐induced liver injury by glatiramer acetate leading to liver transplant: A case report
by: Nikan Amirkhani, et al.
Published: (2023-08-01)

CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate
by: Martin Vališ, et al.
Published: (2019-05-01)

Glatiramer acetate 40 mg/ml: A review of the results of GALA and GLACIER clinical studies
by: N. Yu. Lashch, et al.
Published: (2016-07-01)

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
by: Parry, A, et al.
Published: (2003)